Cowen Starts Kezer Life Sciences (KZR) at Outperform

Cowen initiates coverage on Kezer Life Sciences (NASDAQ: KZR) with a Outperform rating.

Analyst Phil Nadeau comments "KZR-616 is a selective immunoproteasome inhibitor in development for autoimmunity. It is in Ph. Ib in lupus with data expected in H1:19. Proteasome inhibitors have produced P.O.C, and '616's immune selectivity is expected to improve safety/tolerability. We expect '616 to generate much shareholder value as its development progresses."

For an analyst ratings summary and ratings history on Kezer Life Sciences click here. For more ratings news on Kezer Life Sciences click here.

Shares of Kezer Life Sciences closed at $15.80 yesterday.

You May Also Be Interested In

• Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
• Goldman Sachs Downgrades AAC Technologies Holdings Inc. (2018:HK) (AACAY) to Neutral
• Cummins (CMI) PT Lowered to $675 at Jefferies